TY - JOUR
T1 - The microbiome in cancer immunotherapy
T2 - Diagnostic tools and therapeutic strategies
AU - Zitvogel, Laurence
AU - Ma, Yuting
AU - Raoult, Didier
AU - Kroemer, Guido
AU - Gajewski, Thomas F.
N1 - Publisher Copyright:
© 2018 American Association for the Advancement of Science. All right reserved.
PY - 2018/3/23
Y1 - 2018/3/23
N2 - The fine line between human health and disease can be driven by the interplay between host and microbial factors. This "metagenome" regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
AB - The fine line between human health and disease can be driven by the interplay between host and microbial factors. This "metagenome" regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
UR - http://www.scopus.com/inward/record.url?scp=85046048647&partnerID=8YFLogxK
U2 - 10.1126/science.aar6918
DO - 10.1126/science.aar6918
M3 - Review article
C2 - 29567708
AN - SCOPUS:85046048647
SN - 0036-8075
VL - 359
SP - 1366
EP - 1370
JO - Science
JF - Science
IS - 6382
ER -